Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

4 results about "Sedative effect" patented technology

Side Effects of Sedatives. The effects of using sedatives can resemble those of alcohol. In addition to their desired calming effects, sedative use can cause: Drowsiness, dizziness, and confusion. Problems with movement and memory. Slowed heart rate and breathing, which may be worsened if combined with alcohol. Increased risk of falls and injury.

A levorotatory tetrahydropalmatine citrate, its preparation method and application

This invention relates to a levotetrahydropalmatine citrate, its preparation method, and its applications, belonging to the field of pharmaceutical technology. This invention provides a levotetrahydropalmatine citrate. Studies have shown that compared to other salt forms, the citrate form of levotetrahydropalmatine significantly improves its solubility. Furthermore, research has confirmed that levotetrahydropalmatine citrate can significantly reduce drug relapse preferences, with efficacy comparable to or even better than the injectable form, without causing significant adverse reactions and exhibiting good safety. Simultaneously, the sedative effect of levotetrahydropalmatine citrate is far superior to other salt forms. In addition, levotetrahydropalmatine citrate has therapeutic effects on sleep disorders, effectively shortening sleep onset time, increasing sleep duration, and improving sleep quality. Therefore, the levotetrahydropalmatine citrate provided by this invention has broad application prospects in the preparation of drugs for sedation, analgesia, treatment of sleep disorders, and treatment of drug addiction.
Owner:XI AN JIAOTONG UNIV

Steroidal compounds for the treatment of central nervous system disorders, methods of making, uses and pharmaceutical compositions

ActiveCN116606341BChloride channelPharmaceutical drug
The present application provides a steroid compound for treating central nervous system diseases, having a 9β, 10α structure and having the following structural formula: which acts as a GABA modulator, prolongs the opening time of chloride ion channel activated by GABA, modulates the excitability of central nervous system (CNS), treats and prevents CNS related disorders; and the 9β, 10α steroid compound of the present application has a sedative effect and can be used as a sedative.
Owner:HUNAN KYF PHARM CO LTD

Use of benserazide hydrochloride in the preparation of anxiolytic drugs

The application belongs to the technical field of biological medicine, and specifically discloses application of benserazide hydrochloride in preparation of anxiolytic drugs. The application first finds that benserazide hydrochloride plays an anxiolytic role by regulating the kynurenine metabolic pathway. Animal experiments prove that benserazide hydrochloride can promote the generation of kynurenine and its downstream metabolite 3-hydroxyanthranilic acid, and maintain the stable level of 3-hydroxykynurenine, thereby improving the function of the metabolic pathway and restoring the nervous system homeostasis. Behavioral experiments show that benserazide hydrochloride can increase the exploration behavior of zebrafish and reduce the avoidance behavior, and meanwhile, does not cause inhibition of motor function or sedative effect, and shows good safety and selectivity. The application provides a theoretical basis and a new drug source for the prevention and / or treatment of anxiety.
Owner:HUBEI UNIV OF TECH

New compounds with local anesthetic and general deep sedative functions and medical uses

The application provides a new compound with local anesthesia and general deep sedation function and medical use. The new compound has the structure shown in the following formula: The compound has local anesthesia and also exhibits a unique general sedative effect, suggesting that it has general anesthesia potential, and its rapid onset and recovery characteristics make it possible to be used for developing a new intravenous anesthetic.
Owner:XUZHOU MEDICAL UNIVERSITY +1